3α-氨基胆甾烷 - CAS:2206-20-4 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	3α-氨基胆甾烷一键复制产品信息
英文名称:	3α-Aminocholestane
别名:	3α-氨基胆甾烷
CAS No:	2206-20-4	分子式:	C₂₇H₄₉N	分子量:	387.68
CAS No:	2206-20-4
分子式:	C₂₇H₄₉N
分子量:	387.68

点击下载产品说明书(PDF)

A12396 3α-氨基胆甾烷 ≥98% (普西唐-psaitong)

相关产品

包装规格：

5mg 10mg 25mg 50mg 100mg in glass bottle

产品描述：

基本信息

产品编号：	A12396
产品名称：	3α-Aminocholestane
CAS:	2206-20-4	储存条件	粉末	-20℃	四年

分子式：	C27H49N		溶于液体	-80℃	六个月
分子量	387.68			-20℃	一个月
化学名：	3\| inverted exclamation mark-Aminocholestane
Solubility (25°C)：
体外:	DMSO	<1mg/mL(insoluble or slightly soluble)
	Ethanol	50mg/mL(128.97mM;Need ultrasonic)
	Water
体内(现配现用):
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	2.5794mL	12.8972mL	25.7945mL
5mM	0.5159mL	2.5794mL	5.1589mL
10mM	0.2579mL	1.2897mL	2.5794mL

生物活性

产品描述	一种含有选择性SH2结构域的肌醇-5'-磷酸酶1(SHIP1)的抑制剂。
靶点	IC50: 2.5μM (SHIP1)
体外研究	OPM2 cell viability is effectively reduced by 3α-Aminocholestane (3AC) treatment. RPMI8226 and U266 cells show significantly less sensitivity to 3α-Aminocholestane treatment when compare with OPM2 cells, although viability is decreased significantly at concentrations of ≥12.5μM. Treatment with 3α-Aminocholestane for 36 h severely reduces the percentage of cells in the S phase, which is accompanied by an increase of cells in the G2/M phase. In contrast, in the less proliferative RPMI8226 and U266 cells, cell cycle progression is blocked in the G0/G1 phase upon 3α-Aminocholestane treatment, in conjunction with a reduced percentage of cells undergoing the S phase
体内研究	It is found that 3α-Aminocholestane (3AC) results in reduced multiple myeloma (MM) growth in vivo, as determined by quantitation of free human Igλ light chain in the plasma after OPM2 challenge. In addition, reduced numbers of circulating OPM2 cells, as determined by human HLA-ABC staining, is observed in peripheral blood from 3α-Aminocholestane-treated mice compare with vehicle controls. Most importantly, 3α-Aminocholestane treatment results in significantly enhanced survival of mice after tumor challenge. In 3α-Aminocholestane-treated mice that resist treatment, it is found thatmM tumors exhibit an upregulation of SHIP2, reminiscent of in vitro treatment of OPM2 cells and suggesting that SHIP1 inhibition may select for tumor cells with increased SHIP2 expression

推荐实验方法(仅供参考)

Cell Assay

Cells are treated in triplicate or more with increasing concentrations of compounds (including 3α-Aminocholestane). Cell viability is determined with a Cell Counting Kit according to the manufacturer’s instructions. The odds density (OD) of compound (including 3α-Aminocholestane )-treated cells is divided by the OD of their vehicle control, and the viability is expressed as a percentage of untreated cells. Results are expressed as mean±standard error of the mean (SEM) of three individual experiments. For phosphatidyl inositol phosphates (PIP) add-back experiments, MCF-7 cells are treated for 2 h with 10μM SHIP inhibitors (including 3α-Aminocholestane ), after which cells are washed and fresh medium is added. Cells are subsequently cultured in the absence (0μM) or presence (10 or 20μM) of either PtdIns(3,4)P2-diC16 (P-3416) or PtdIns(3,5)P2-diC16 (P-3516) for 36 h, after which cell viability is determined by the Cell Counting Kit

Animal Administration

NOD/SCID/γcIL2R (NSG) mice are injected intraperitoneally with 1×10⁷ OPM2 cells and 6 h later receive an initial injection of 3α-Aminocholestane (3AC) or vehicle. 3α-Aminocholestane is suspended in a 0.3% Klucel/H2O solution at 11.46mM and administered by intraperitoneal injection of 100μL solution. Vehicle-treated mice receive 100μL injection of 0.3% Klucel/H2 O solution. The mice are then treated with 3α-Aminocholestane or vehicle daily for the next 6 d and then twice per week in the remaining 15 wks of the survival study

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)